National and Kapodistrian University of Athens
Design, Synthesis and biological evaluation of drug-like molecules bearing an adamantane moiety against targets of therapeutic interest in human deseases
Abstract
dc:descriptionSoluble epoxide hydrolase plays a crucial role in the metabolism of epoxyeicosanoids, which are important mediators in inflammation and pain pathways. The inhibition of soluble epoxide hydrolase can increase the levels of these beneficial epoxides, resulting in anti-inflammatory and analgesic effects. Adamantyl ureas can fit the hydrophobic pocket of soluble epoxide hydrolase, and the combination with other lipophilic moieties, e.g., the 1-acetylpiperidinyl group, was found to lead to potent urea soluble epoxide hydrolase inhibitors with promising results in preclinical and clinical studies for conditions, including hypertension, pain, and other inflammatory diseases. We explored structure-activity relationships in these urea derivatives with various adducts on adamantyl. Interestingly, we observed that ureas consisting of the 1-adamantyl-phenyl or the 2-adamantyl-phenyl and the 1-acetylpiperidinyl group endowed with promising potency and in vitro pharmacokinetic properties. The X-ray crystal structures combined with molecular dynamics simulations of these compounds showed that 1-adamantyl was positioned on the right-hand side of the binding area, while the 2-adamantyl group occupied the left-hand side.Experimental structures have shown that the cannabinoid receptor type 2 features a deep, hydrophobic orthosteric binding site within its transmembrane region that is well-suited to accommodate tightly large, rigid structures, such as hydrocarbon cage alkyl groups through hydrophobic interactions. Based on these structural features, we investigated a series of ureas consisting of N-(2-adamantyl) and bearing rigid bicyclic groups, i.e., the N-(1-tetrahydroquinolinyl) or the N-(1-dihydroindolyl) moieties. The new derivatives act as agonists and are endowed with low nanomolar potency, excellent selectivity for the cannabinoid receptor type 2 over the cannabinoid receptor type 1. Preliminary experiments showed that the most promising compounds act as agonists. These results highlight the potential of optimized adamantane derivatives in the development of potent and selective cannabinoid receptor type 2 modulators.N1-(adamantan-2-yl)-N2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]ethane-1,2-diamine(SQ109) is a candidate drug against Mycobacterium tuberculosis that is anticipated to function by at least partially inhibiting the mycobacterial membrane protein large transporter type 3 (MmpL3) transporter to block cell wall biosynthesis. It also exhibits activity against bacteria and protozoan parasites that lack MmpL3, where it can function as an uncoupler, focusing on lipid membranes and Ca2+ homeostasis. In this study, we synthesized 22 analogs of SQ109 bearing substituted phenyl and benzyl adducts attached at the C2 adamantyl position and tested them along with the liposomic forms for selected analogs against different parasites, including Staphylococcus aureus, along with a panel of antibiotic-resistant strains, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Klebsiella aerogenes, Mycobacterium tuberculosis, Mycobacterium abscessus, and the protozoan Plasmodium falciparum. The new phenyl or benzyl adducts were 4-16-fold more active than SQ109 against Gram-positive bacterial panels and multidrug-resistant strains, as well as against M. abscessus, and some were found potent against M. tuberculosis and P. falciparum. These findings support the continued development of aryl-substituted SQ109 derivatives, as promising broad-spectrum agents targeting both mycobacteria and non-mycobacterial pathogens.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Laro, Jorgo
- Λάρος, Γιώργος
Subjects
dc:subject × 8Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61237